SERPINB2

Chr 18

serpin family B member 2

Also known as: HsT1201, PAI, PAI-2, PAI2, PLANH2

The SERPINB2 protein inhibits urokinase-type plasminogen activator, functioning as a serine protease inhibitor involved in regulating fibrinolysis and apoptosis. Mutations cause plasminogen activator inhibitor-2 deficiency, inherited in an autosomal recessive pattern. This gene shows very low constraint against loss-of-function variants, which is consistent with recessive inheritance where heterozygous carriers are typically unaffected.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
31
Pubs (1 yr)
100
P/LP submissions
0%
P/LP missense
1.53
LOEUF
Multiple*
Mechanism· predicted
Clinical SummarySERPINB2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
97 unique Pathogenic / Likely Pathogenic· 61 VUS of 179 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.53LOEUF
pLI 0.000
Z-score -0.09
OE 1.02 (0.701.53)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
-0.77Z-score
OE missense 1.15 (1.031.27)
257 obs / 224.4 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE1.02 (0.701.53)
00.351.4
Missense OE1.15 (1.031.27)
00.61.4
Synonymous OE1.23
01.21.6
LoF obs/exp: 17 / 16.6Missense obs/exp: 257 / 224.4Syn Z: -1.65
DN
0.7326th %ile
GOF
0.6833th %ile
LOF
0.2190th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

179 submitted variants in ClinVar

Classification Summary

Pathogenic90
Likely Pathogenic7
VUS61
Likely Benign9
Benign6
90
Pathogenic
7
Likely Pathogenic
61
VUS
9
Likely Benign
6
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
90
0
90
Likely Pathogenic
0
0
7
0
7
VUS
0
48
13
0
61
Likely Benign
0
8
0
1
9
Benign
0
2
1
3
6
Total0581114173

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SERPINB2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →